The company has reported a net loss of $18.4m, compared to net loss of $16.25m, for the same period last year.
The company’s loss from operations was $18.54m, as compared to $14.5m for the same period prior year.
Ironwood said it will continue to advance its pipeline, which includes product candidates and research efforts focused on gastrointestinal disease, pain and inflammation, respiratory and allergic disease, and cardiovascular disease.
Based on its current operating plan, Ironwood continues to target ending fiscal year 2011 with greater than $150m of cash, cash equivalents, and available-for-sale securities.